Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Novartis AG
  6. News
  7. Summary
    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Bryan Garnier Downgrades Novartis to Neutral from Buy

12/03/2021 | 09:40am EST


ę MT Newswires 2021
All news about NOVARTIS AG
01/26BioNTech Plans 50% Workforce Boost, $57 Million Investment At German Factory
MT
01/25Merus Regains Worldwide Rights to MCLA-145 After Incyte Opt-Out; Names Chief Commercial..
MT
01/25NOVARTIS AG : Goldman Sachs gives a Buy rating
MD
01/25AlphaValue/Baader Europe Lowers Price Target on Novartis, Upgrades Recommendation to Bu..
MT
01/24NOVARTIS : 2021 Global Managed Access Program Community Update
PU
01/20BAUSCH HEALTH BRIEF : He Will join Bausch + Lomb from Allergan/AbbVie; Prior to that, he w..
MT
01/20NOVARTIS AG : JP Morgan keeps a Sell rating
MD
01/20"SHOW MORE OF YOU" : Amgen V. Sandoz, Battling It Out On Amgen's Otezla« Drug
AQ
01/18Novartis CEO Expects Worldwide Normalcy to COVID-19 By 2022-End
MT
01/18GLOBAL MARKETS LIVE : Toyota, Microsoft, Goldman Sachs, Alibaba, Boeing...
More news
Analyst Recommendations on NOVARTIS AG
More recommendations
Financials (USD)
Sales 2021 51 984 M - -
Net income 2021 23 343 M - -
Net Debt 2021 8 126 M - -
P/E ratio 2021 8,23x
Yield 2021 3,83%
Capitalization 191 B 191 B -
EV / Sales 2021 3,82x
EV / Sales 2022 3,68x
Nbr of Employees 108 000
Free-Float -
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | MarketScreener
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 85,21 $
Average target price 98,65 $
Spread / Average Target 15,8%
EPS Revisions
Managers and Directors
Vasant Narasimhan Chief Executive Officer
Harry Werner Kirsch Chief Financial Officer
Hans J÷rg Reinhardt Independent Non-Executive Chairman
John Tsai Chief Medical Officer
Klaus Moosmayer Chief Ethics Risk & Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVARTIS AG-1.13%190 894
JOHNSON & JOHNSON0.42%452 254
ROCHE HOLDING AG-6.24%308 691
PFIZER, INC.-7.99%304 947
ABBVIE INC.1.86%243 826
ELI LILLY AND COMPANY-11.27%222 206